Castle Biosciences Inc reports results for the quarter ended in March - Earnings Summary

Castle Biosciences

03/05/2023 22:03

* Castle Biosciences Inc  CSTL.OQ  reported a quarterly
adjusted
loss of $1.10​​ per share for the quarter ended in March. The
mean expectation of eight analysts for the quarter was for a
loss of 89 cents per share.
    * Revenue rose 56.6% to $42.04 million from a year ago;
analysts
expected $37.37 million. 
    * Castle Biosciences Inc's reported EPS for the quarter was
a loss
of $1.10​.
    * The mean earnings estimate of analysts had fallen by
about 5.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Castle Biosciences Inc shares had fallen by 2.9% this
quarter and lost 6.3% so far this year.
    * The company reported a quarterly loss of $29.2 million.
    * Wall Street's median 12-month price target for Castle
Biosciences Inc is $41.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
3 at 09:02 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.89          -1.10          Missed
 Dec. 31 2022      -0.84          -0.78          Beat
 Sep. 30 2022      -0.88          -0.77          Beat
 Jun. 30 2022      -0.76          -0.06          Beat